---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-252642"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:00.969464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Q3 net revenues $16.4M, up >120% QoQ; net loss $85.6M; VOQUEZNA prescriptions exceed 143k launch-to-date

## Summary
- Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.
- Over 143,000 prescriptions for VOQUEZNA products filled launch-to-date (138% increase since last quarterly report).
- Net loss $85.6M vs $43.2M in Q3 2023; non-GAAP adjusted net loss $67.9M vs $30.8M.
- Commercial access expanded to >80% of U.S. commercial lives (est. 120M covered lives).
- R&D expenses down to $8.7M; SG&A up to $76.1M due to commercial buildout.

## SEC filing metadata
- accession: 0001193125-24-252642
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/0001193125-24-252642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524252642/d885289d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-252642
- JSON: https://secwatch.observer/filing/0001193125-24-252642.json
- Plain text: https://secwatch.observer/filing/0001193125-24-252642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.